Estrella Immunopharma (ESLA) Retained Earnings (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Retained Earnings of $34.6 million for Q1 2026, up 233.1% year-over-year from $10.4 million in Q1 2025, and up 27.14% quarter-over-quarter from $27.2 million in Q4 2025.
Estrella Immunopharma (ESLA) Retained Earnings (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Retained Earnings for 6 consecutive years, with $34.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 233.1% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (up 233.1% YoY), while the FY2025 annual figure was $27.2 million, up 10.48% from the prior year.
- Retained Earnings grew to $34.6 million in Q1 2026 per ESLA's latest filing, from $27.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at $34.6 million in Q1 2026 and bottomed at -$36.4 million in Q3 2025.
- Historically, Retained Earnings has averaged -$6.8 million across 5 years, with a median of -$12.2 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings sank 708.7% — and 2024, when it soared 263.15%.
- Estrella Immunopharma's Retained Earnings stood at -$2.3 million in 2022, then slumped by 569.38% to -$15.1 million in 2023, then jumped by 263.15% to $24.6 million in 2024, then climbed by 10.48% to $27.2 million in 2025, then rose by 27.14% to $34.6 million in 2026.
- Business Quant data shows ESLA's Retained Earnings at $34.6 million in Q1 2026, $27.2 million in Q4 2025, and -$36.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 4.38 Bn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -41.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.60 Mn |
| Mar 31, 2026 | 34.61 Mn |
| Dec 31, 2025 | 27.22 Mn |
| Sep 30, 2025 | -36.38 Mn |
| Jun 30, 2025 | -31.58 Mn |
| Mar 31, 2025 | -26.00 Mn |
| Dec 31, 2024 | 24.64 Mn |
| Sep 30, 2024 | -22.90 Mn |
| Jun 30, 2024 | -19.50 Mn |
| Mar 31, 2024 | -15.50 Mn |
| Dec 31, 2023 | -15.10 Mn |
| Sep 30, 2023 | -14.06 Mn |
| Jun 30, 2023 | -12.19 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -2.26 Mn |
| Sep 30, 2022 | -1.98 Mn |
| Jun 30, 2022 | -1.51 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -1.01 Mn |
| Sep 30, 2021 | -870,537.00 |